PharmaMar presents new data on Zepzelca® (lurbinectedin) in combination with irinotecan at an oral session at (rescheduled) IASLC 2020

The Objective Response Rate (ORR) is 62% and a median Progression Free Survival (PFS) 6.2 months in second and third line patients with Small Cell Lung Cancer (SCLC). Lurbinectedin’s activity in combination with irinotecan is strong in sensitive patients (CTFI≥90) with an ORR of 69% and a median PFS of 8.1 months. The activity is very encouraging in resistant patients (CTFI<90), with an ORR of 50% and a median PFS of 4.8 months. Also noteworthy is the activity demonstrated by this combination in third-line patients, with an ORR of 38% and a median PFS of 4.2 months. The combination has shown a well-tolerated and manageable safety profile. PharmaMar (MSE:PHM), along with Jazz Pharmaceuticals plc (Nasdaq: JAZZ), have announced today that new data for Zepzelca® (lurbinectedin) in combination with irinotecan have been presented at an oral session during the IASLC 2020 World Lung Cancer Conference, which has been held virtually from January 28th-31st. Santiago Ponce, M.D., oncologist at the Hospital 12 de Octubre in Madrid, and one of the principal investigators of the study titled “EFFICACY AND SAFETY PROFILE OF LURBINECTEDIN-IRINOTECAN IN PATIENTS WITH RELAPSED SCLC. Results from a Phase Ib-II trial“, highlighted that the combination of lurbinectedin with irinotecan proved to be effective in patients with Small Cell Lung Cancer (SCLC), after failure of first-line therapy, with particularly notable activity in patients with resistant disease (Chemotherapy-Free Interval CTFI <90 days) and also in 3rd line treatment. Data have been presented for a total of 21 evaluable patients with SCLC who had progressed after receiving at least one prior line of platinum-based chemotherapy. The Objective Response Rate (ORR) was 62%, with a median Progression Free Survival (PFS) of 6.2 months. The activity of lurbinectedin in combination with irinotecan is particularly notable in sensitive patients (CTFI≥90) with an ORR of 69% and a median PFS of 8.1 months. Noteworthy is the activity demonstrated by this combination in third-line treatment, with an ORR of 38% and a median PFS of 4.2 months. The activity is very encouraging in resistant patients (CTFI<90), with an ORR of 50% and a median PFS of 4.8 months. The combination has shown a manageable safety profile, toxicities being mainly hematological abnormalities, fatigue and diarrhea, all of which were transient. There have been no deaths due to toxicity and no patients have discontinued treatment due to treatment-related toxicity. It is planned to have a total of 47 patients in the cohort of this trial, and complete data will be presented at a future congress. All studies presented at the reschedule IASLC 2020 Congress are available at: https://library.iaslc.org/conference-program?product_id=20

The release as fetched from its publisher. pharmamar.com ↗